MapLight Therapeutics, Inc. 8-K

What Happened

• On March 26, 2026, MapLight Therapeutics, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025 via a press release furnished on Form 8-K (Item 2.02).
• The company also updated its corporate presentation for investor meetings and furnished that presentation on the same Form 8-K under Regulation FD (Item 7.01). The Form 8-K was signed by CEO Christopher A. Kroeger, M.D.

Key Details

• Filing date: March 26, 2026. Reporting periods: Q4 2025 and full year ended December 31, 2025.
• Press release with the financial results is furnished as Exhibit 99.1 to the 8-K.
• Updated investor/corporate presentation is furnished as Exhibit 99.2 and is available on the company’s website.
• The 8-K furnishes the materials (press release and presentation) rather than embedding full financial statements in the filing.

Why It Matters

• This 8-K provides the company’s latest earnings and quarterly results information and an updated presentation investors use to assess revenue, expenses, cash position and near‑term outlook.
• Retail investors should review the press release and presentation (Exhibits 99.1 and 99.2 or the company website) for the specific financial figures, any commentary on revenue, profitability, cash runway or guidance that could affect the stock.